Investor Relations

Latest Financial Results

Q3 2021

Quarter Ended Dec 31, 2020

Latest Annual Filing

Fiscal Year Ended Mar 31, 2020

View Filing

Stock Information

Company Overview

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that includes 3 to 4 million patients in the U.S. Acasti may need to conduct at least one additional clinical trial to support FDA approval of a supplemental New Drug Application to expand CaPre's indications to this segment. Acasti's strategy is to commercialize CaPre in the U.S. and the company is pursuing development and distribution partnerships to market CaPre in major countries around the world.

Investor Presentation

Investor Presentation

Download Investor Presentation


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5

Investor Relations

Crescendo Communications, LLC
626 RXR Plaza
Uniondale, NY 11566
T: 212-671-1020

Transfer Agent

Computershare Trust Company of Canada
650 de Maisonneuve West
7th Floor
Montreal, QC H3A 3T2
T: 514-982-7888